Reglan Tardive Dyskinesia Settlement: Key Factors in Claim Valuation
Latest update (2025-07)
FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]
From General Health Information to Targeted Risk Assessment
For decades, general health information resources have served as foundational tools for public education, offering broad guidance on wellness, disease prevention, and the appropriate use of medical services. These materials typically emphasize the importance of informed patient-provider communication and adherence to prescribed treatments. Within this legacy context, discussions of medication safety often remain at a general level, focusing on common side effects and the necessity of monitoring. However, as clinical practice evolves, certain therapeutic exposures warrant more targeted scrutiny. One such area involves the long-term or high-dose use of metoclopramide, commonly known by the brand name Reglan, which has been associated with a distinct neurological condition. This shifts the focus from general health maintenance toward a specific occupational and clinical concern: the assessment of risk factors for individuals who have been exposed to this medication. In mass production environments, where standardized treatment protocols may be applied across large patient populations, the potential for widespread exposure becomes a critical consideration. The transition from general health education to evaluating Reglan-related tardive dyskinesia claims requires careful attention to the factors that influence individual vulnerability, including duration of therapy, cumulative dosage, and patient demographics.
Epidemiological data on TD incidence with oral metoclopramide use have varied. A real-world study using the MarketScan Research database (2011-2020) analyzed TD incidence in adults with at least 12 months of medical and pharmacy benefits, comparing rates among metoclopramide-treated gastroparesis patients, untreated patients, and the general population (https://pubmed.ncbi.nlm.nih.gov/41588797/). This study aimed to reassess TD risk given inconsistent estimates from older studies, which ranged from 1% to 15% (https://pubmed.ncbi.nlm.nih.gov/41588797/). Another analysis, based on a literature search of PubMed, Google Scholar, and cross-references, reported that the risk of TD from metoclopramide is low, approximately 0.1% per 1000 patient-years, which is far below the previously estimated 1%-10% risk suggested in treatment guidelines (https://pubmed.ncbi.nlm.nih.gov/31050085/). This same source identified high-risk groups including elderly females, diabetics, patients with liver or kidney failure, and those on concomitant antipsychotic drug therapy, which reduces the threshold for neurological complications (https://pubmed.ncbi.nlm.nih.gov/31050085/). The adequacy of warnings regarding Reglan and TD is addressed in the boxed warning and precautions sections of the prescribing information. The boxed warning explicitly states that metoclopramide can cause TD, that risk increases with treatment duration and cumulative dose, and that Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). It also directs prescribers to use the shortest treatment duration and to discontinue Reglan immediately if signs or symptoms of TD develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Settlement Valuation Factors
Despite these warnings, litigation has arisen from claims that patients were not adequately informed of the risk, particularly in cases of long-term use beyond recommended durations. Settlement considerations for affected patients typically involve factors such as the severity and irreversibility of TD symptoms, duration of Reglan exposure, presence of other risk factors (e.g., age, diabetes, concomitant antipsychotic use), and the timeline between exposure and documented harm. The boxed warning emphasizes that TD can be a serious, potentially irreversible condition, which may influence compensation in legal claims (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The timeline between exposure and harm is critical: TD may develop after months or years of metoclopramide use, and the risk increases with cumulative dose (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, the condition can also appear after discontinuation, and metoclopramide may mask early signs, complicating diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In settlement contexts, these factors are weighed alongside the strength of evidence linking the patient's TD to Reglan use, the adequacy of prescriber warnings, and the presence of any contributing comorbidities or concurrent medications.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is Reglan and how is it linked to tardive dyskinesia?
Reglan (metoclopramide) is a medication used to treat gastrointestinal disorders. It is associated with tardive dyskinesia (TD), a potentially irreversible movement disorder. The FDA boxed warning states that the risk of TD increases with duration of treatment and cumulative dose (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
What factors influence the valuation of a Reglan TD claim?
Key factors include severity and irreversibility of TD symptoms, duration and dosage of Reglan exposure, presence of other risk factors (e.g., age, diabetes, antipsychotic use), timeline between exposure and harm, and strength of evidence linking TD to Reglan. The boxed warning emphasizes that TD can be serious and potentially irreversible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
What does the FDA boxed warning say about Reglan and TD?
The boxed warning states that metoclopramide can cause TD, risk increases with treatment duration and cumulative dose, and Reglan is contraindicated in patients with a history of TD. It advises using the shortest treatment duration and discontinuing immediately if TD signs develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.